AbstractObjective To investigate whether prophylactic intracoronary administration of nicodil can reduce the incidence of NRP in STEMI patients undergoing PCI. Methods A total of 280 patients with persistent acute STEMI and suitable for inpatient PCI who received treatment were selected and divided into observation group（140 cases）and control group（140 cases）according to the double-blind method.The incidence of NRP,interleukin 6 and the levels of hs-CRP,cTnT and CK-MB were observed every 4 hours before and after PCI.And major adverse cardiovascular events at day 30. Results The incidence of NRP in the observation group was 24%,which was significantly lower than that in the control group（P<0.05）.Seven days after surgery,The observation group NT-proBNP（607.31±82.20）ng·L-1,CK-MB（328.00±77.95）U·L-1,cTnI（3.14±0.55）μg·L-1 were significantly less than the control group NT-proBNP（734.47±82.60）ng·L-1,CK-1MB（440.89±88.94）U·L-1,cTnI（4.48±1.00）μg·L-1（P<0.05）.Before surgery,there were no significant differences in NT-proBNP,CK-MB and cTnI between the two groups（P>0.05）.At 7 days after operation,LVEF in the observation group was significantly higher than that in the control group（P<0.05）.At 7 days postoperatively,WMSI in the observation group was significantly lower than that in the control group（P<0.05）.Before surgery,there was no significant difference in LVEF and WMSI between the two groups（P>0.05）.The observation group（0 cases of hypotension and 6 cases of major cardiac adverse events）were significantly lower than the control group（14 cases of hypotension and 28 cases of major cardiac adverse events）（P<0.05）. Conclusion The results of this study will determine the effectiveness of prophylactic intracoronary administration of nicodil to reduce the incidence of NRP during PCI in patients with acute STEMI.
[1] Antman EM,Anbe DT,Armstrong PW,et al.ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction executive summary[J].Am Coll Cardiol 2018,44(5):671-719. [2] O’gara PT,Kushner FG,Ascheim DD,et al.2017ACCF/AHA guideline for the management of ST-elevation myocardial infarction:executive summary:a report of the American College of Cardiology Foundation[J].Circulation 2017,127(22):529-555. [3] 郑泽,范谦,彭红玉,等.既往冠状动脉旁路移植术患者慢性完全闭塞病变行经皮冠状动脉介入治疗[J].中国介入心脏病学杂志,2020,178(5):12-16. [4] Alyamani M,Campbell S,Navarese E,et al.SafetySafety and efficacy of intracoronary thrombolysis as adjunctive therapy to primary PCI in STEMI:a systematic review and meta-analysis[J].Can J Cardiol,2021,37(64):339,346. [5] 吴玉成,李云升,桑运锋,等.不同剂量阿托伐他汀对急性ST段抬高型心肌梗死患者急诊PCI术后无复流现象发生和心功能的影响[J].临床和实验医学杂志,2019,25(2):16-19. [6] Celik T,Balta S,Ozturk C,et al.Predictors of no-reflow phenomenon in young patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Angiology 2016,67(221):683-689. [7] 张成茹. 冠脉内选择性应用尼可地尔对STEMI患者直接PCI术后无复流防治的有效性及安全性研究[J].河北大学,2020,68(31):64-68. [8] Kobatake R,Sato T,Fujiwara Y,et al.Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction[J].Heart Vessels 2011,26(44):379-384. [9] 姚晶,宋莉,刘臣,等.真实世界中延迟与急诊经皮冠状动脉介入治疗并置入药物洗脱支架对ST段抬高型心肌梗死患者远期预后的影响[J].中国心血管杂志,2020,25(3):214-219. [10] 吴玉成,李云升,桑运锋,等.不同剂量阿托伐他汀对急性ST段抬高型心肌梗死患者急诊PCI术后无复流现象发生和心功能的影响[J].临床和实验医学杂志,2019,28(8):159-162. [11] Movahed MR,Butman SM.The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention[J].Cardiovasc Revasc Med 2008,9(55):56-61. [12] 刘勇,姜东伟.ST段抬高型心肌梗塞患者血小板淋巴细胞比率与左冠状动脉前降支病变位置的关系研究[J].中国卫生检验杂志,2019,29(7):844-846. [13] 关心. 尼可地尔对行 PCI 冠心病患者血管内皮功能及血清炎性反应的影响[J].心血管康复医学杂志,2019,28(3):337-341. [14] 薛增明,李雅超,杨彦立,等.麝香保心丸联合尼可地尔对心肌梗死后冠脉微循环障碍患者心脏功能和血流动力学水平的影响[J].中国煤炭工业医学杂志,2020,23(1):76-80. [15] Lenz M,Kaun C,Krychtiuk KA,et al.Effects of nicorandil on inflammation,apoptosis and atherosclerotic plaque progression[J].Biomedicines 2021,9(65):120-322.
2022, Vol. 42 
